Advances in protein kinase B inhibitor capivasertib for breast cancer treatment
GENG Ji-hong
QUAN Xiang-hua
ZHAO Jun
DU Cai-ying
SUN Cai-hong
YUAN Hai-dan
Abstract：Capivasertib,a protein kinase B(AKT)inhibitor,was officially approved by the U.S.FDA on November 16,2023.The 2024 Chinese Society of Clinical Oncology Breast Cancer Diagnosis and Treatment Guidelines recommends it as a treatment option for the failure of endocrine therapy combined with cyclin-dependent kinase 4/6 inhibitor in patients with advanced breast cancer.Currently,the domestic listing application is under review.As the world's first approved AKT inhibitor,capivasertib,in combination with fulvestrant,can improve the median progression-free survival and overall survival of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.It has a good safety profile,thus being a promising application prospect.
Keywords：capivasertibbreast cancerprotein kinase B inhibitor
Publication Date：2025-03-14
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：7( 483-489 )